ArticleJournal of food and drug analysis2025
Yi-Qi-Xuan-Fei Formula ameliorate chronic obstructive pulmonary disease by remodeling lung and intestinal florase in rat models.
Article in Journal of food and drug analysis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Modulation of microbiota by traditional Chinese medicine in chronic inflammatory airway disease: a systematic review and meta-analysis of animal studies.Frontiers in immunology · 2026Pooled it
Corrections and comments
- Erratum issued
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic obstructive pulmonary disease (COPD) is a chronic respiratory disease characterized by various pathological lesions and an imbalance in the microflora. The Yi-Qi-Xuan-Fei Formula (YQXF) is a clinically effective formula with pharmacological potential to delay the progression of COPD. This study aims to explore the relationship between the therapeutic mechanism of YQXF and the microflora in COPD. Our study found that YQXF reduces inflammatory injury and inflammatory cell infiltration in lung tissue, repairs the intestinal mucosal barrier, and enhances immune function. Additionally, YQXF regulates the pulmonary and intestinal flora by increasing the abundance of Alloprevotella, Roseburia, Oscillibacter, and Lactobacillus, while reducing the abundance of Fusobacterium, Escherichia/Shigella, and Clostridium sensu stricto. Moreover, YQXF elevates the levels of short-chain fatty acids, which are produced by the intestinal flora. In conclusion, our findings demonstrate that YQXF reduces inflammation levels in lung tissue and repairs the intestinal barrier in COPD rats. Furthermore, the anti-inflammatory and tissue damage prevention effects of YQXF are based on its intervention in the pulmonary and intestinal flora. These findings provide valuable insights into the fundamental mechanism of the herbal formula YQXF and suggest that specifically targeting the intestinal flora could be a potential therapeutic approach for COPD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.